{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:56Z","timestamp":1788778856919,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The treatment paradigm in newly diagnosed multiple myeloma (NDMM) is evolving toward individualized, risk\u2010directed, and longer duration of therapy (DOT). The objective of this study was to describe treatment patterns and outcomes in non\u2010transplant NDMM in four European countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective chart review included adults with NDMM diagnosed between January 1, 2012, and December 31, 2013 (early cohort), or April 1, 2016, and March 31, 2017 (recent cohort).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 836 patients, molecular testing was performed in 21% and 35% patients of early vs recent cohorts; proteasome inhibitor (PI)\/alkylator combinations were the principal first\u2010line (1\u00a0L) therapy (39% vs 43%). Use of immunomodulatory drug (IMID)\/alkylator combinations declined from early to recent cohort (26% vs 13%) but IMID (7% vs 16%) use increased. Few patients (5%) received 1\u00a0L maintenance therapy. Two\u2010thirds of patients were treated with a fixed duration intent, with a median 7\u2010month 1\u00a0L DOT and progression\u2010free survival (PFS) of 32.8\u00a0months in the early cohort. Both 1\u00a0L DOT and PFS were longer with oral compared to injectable regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although frontline treatment patterns changed significantly, 1\u00a0L DOT is short. The uptake of molecular testing and 1\u00a0L maintenance is low. These results highlight areas of unmet need in NDMM.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13439","type":"journal-article","created":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T15:59:50Z","timestamp":1589731190000},"page":"308-325","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real\u2010world treatment patterns and outcomes in non\u2010transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"H\u00f4pital Saint\u2010Antoine Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire Sorbonne University Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Knauf","sequence":"additional","affiliation":[{"name":"Center for Hematology and Oncology Agaplesion Bethanien Hospital Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[{"name":"Global Outcomes Research and Epidemiology Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-2971","authenticated-orcid":false,"given":"Shelby","family":"Corman","sequence":"additional","affiliation":[{"name":"Pharmerit International Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Verleger","sequence":"additional","affiliation":[{"name":"Pharmerit International Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngmin","family":"Kwon","sequence":"additional","affiliation":[{"name":"Pharmerit International Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[{"name":"Global Outcomes Research and Epidemiology Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Janelle","family":"Cambron\u2010Mellott","sequence":"additional","affiliation":[{"name":"Kantar Health New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris G.","family":"Vikis","sequence":"additional","affiliation":[{"name":"Kantar Health New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Gavini","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099358"},{"key":"e_1_2_6_3_1","first-page":"1","article-title":"Italian cancer figures\u2013Report 2015: The burden of rare cancers in Italy","volume":"40","author":"Airtum Working Group","year":"2016","journal-title":"Epidemiol Prev"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.005"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19269"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.11.016"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0272-0"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_6_16_1","unstructured":"Cancer Research UK.Myeloma incidence statistics.https:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/myeloma\/incidence#ref\u2010. Accessed 28\u201006\u20102019"},{"key":"e_1_2_6_17_1","unstructured":"Robert Koch Institut.Inzidenz Plasmozytom (C90).https:\/\/www.krebsdaten.de\/Krebs. Accessed 28\u201006\u20102019"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196596"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0426"},{"key":"e_1_2_6_20_1","unstructured":"National Comprehensive Cancer Network (NCCN).NCCN Guidelines Version 1.2019: Multiple Myeloma.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed September 20 2018"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208507"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12685"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1798"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.118182"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_6_29_1","unstructured":"National Institute for Health and Clinical Excellence (NICE).Final appraisal determination: Bortezomib and thalidomide for the first\u2010line treatment of multiple myeloma.https:\/\/www.nice.org.uk\/guidance\/ta228\/documents\/multiple\u2010myeloma\u2010first\u2010line\u2010bortezomib\u2010and\u2010thalidomide\u2010final\u2010appraisal\u2010determination3. Accessed January 21 2020"},{"key":"e_1_2_6_30_1","unstructured":"KortumM DriessenC EinseleH et al.Multiple myeloma: 2013 German guidelines.https:\/\/www.onkopedia.com\/de\/onkopedia\/archive\/guidelines\/multiples\u2010myelom\/version\u201010042018T124640\/@@guideline\/html\/index.html. Accessed March 12 2020"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1445-y"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2015.1080833"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795047"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-00184-9"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2016.110"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.212"},{"key":"e_1_2_6_43_1","first-page":"1019","article-title":"Costs associated with productivity loss among U.S. patients newly diagnosed with multiple myeloma receiving oral versus injectable","volume":"24","author":"Merola D","year":"2018","journal-title":"Chemotherapy. J Manag Care Spec Pharm"},{"key":"e_1_2_6_44_1","first-page":"3087","article-title":"&quot;Real World&quot; Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma: A Combined Study from the Greek","volume":"130","author":"Terpos E","year":"2017","journal-title":"Czech and UK Databases. Blood"},{"key":"e_1_2_6_45_1","unstructured":"American Thrombosis & Hemostasis Network.ATHN Research Report Brief \u2010 September 30 2017.https:\/\/athn.org\/documents\/document_file\/302. Accessed August 28 2018"},{"key":"e_1_2_6_46_1","unstructured":"DaviesF RifkinR CostelloC et al.Comparative effectiveness of triplets containing bortezomib (B) Carfilzomib (C) Daratumumab (D) or Ixazomib (I) in relapsed\/refractory multiple myeloma (RRMM) in routine care in the US. Poster presented at: European Hematology Association (EHA) 24th Congress 2019; Amsterdam The Netheralands."},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2014.11.010"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T06:54:09Z","timestamp":1693896849000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/ejh.13439"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13439","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"2020-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}